Table 1.
iQuaD clinical behaviour targeted | Behavioural performance from iQuaD | NICE quality standard a |
---|---|---|
1. Over the past 12 months provided general education about diabetes for patients with type 2 diabetes |
Received by 73% of patients (via patient survey) |
QS1 - ‘People with diabetes and/or their carers receive a structured educational programme that fulfils the nationally agreed criteria from the time of diagnosis, with annual review and access to ongoing education’ |
2. Over the past 12 months provided advice about weight management to patients with type 2 diabetes whose BMI is above a target of 30 kg/m2 even following previous management |
Received by 51% of people whose BMI was above a target of 30 kg/m2, even following previous management (via patient survey) |
QS2 - ‘People with diabetes receive personalised advice on nutrition and physical activity from an appropriately trained healthcare professional or as part of a structured educational programme’ |
3. Over the past 12 months provided advice about self-management for patients with type 2 diabetes |
Received by 68% of patients (via patient survey) |
QS3 - ‘People with diabetes participate in annual care planning which leads to documented agreed goals and an action plan’ |
4. Over the past 12 months prescribed additional therapy for the management of glycaemic control (HbA1c) in patients with type 2 diabetes whose HbA1c is higher than 64 mmol/mol (8.0%) despite maximum dosage of two oral hypoglycaemic drugs |
Received by 59% of people whose HbA1c was higher than 8.0%, despite maximum dosage of two oral hypoglycaemic drugs (via practice-held prescribing data) |
QS4 - ‘People with diabetes agree with their healthcare professional a documented personalised HbA1c target, usually between 48 mmol/mol and 58 mmol/mol (6.5% and 7.5%), and receive an ongoing review of treatment to minimise hypoglycaemia’ |
QS5 - ‘People with diabetes agree with their healthcare professional to start, review and stop medications to lower blood glucose, blood pressure and blood lipids in accordance with NICE guidance’ | ||
5. Over the past 12 months prescribe additional antihypertensive drugs for patients with type 2 diabetes whose blood pressure is 5 mmHg above target of 140 mmHg (systolic) or 80 mmHg (diastolic) even following previous management |
Received by 40% whose blood pressure (BP) is above a target of 140 mm Hg for Systolic BP or 80 mm Hg for Diastolic BP, even following previous management (via practice-held prescribing data) |
QS5 - ‘People with diabetes agree with their healthcare professional to start, review and stop medications to lower blood glucose, blood pressure and blood lipids in accordance with NICE guidance’ |
6. Over the past 12 months examined foot circulation and sensation in the feet of patients with type 2 diabetes |
Received by 91% of patients (via patient survey) |
QS10 - ‘People with diabetes at risk of foot ulceration receive regular review by a foot protection team in accordance with NICE guidance’ |
QS11 - ‘People with diabetes with a foot problem requiring urgent medical attention are referred to and treated by a multidisciplinary foot care team within 24 hours’ |
aFrom NICE quality standard for diabetes in adults (http://www.nice.org.uk/media/7F8/B2/DiabetesQualityStandard.pdf).
Note. QOF = Quality and Outcomes Framework.